650 related articles for article (PubMed ID: 17363602)
21. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
23. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
24. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
Tsao AS; He D; Saigal B; Liu S; Lee JJ; Bakkannagari S; Ordonez NG; Hong WK; Wistuba I; Johnson FM
Mol Cancer Ther; 2007 Jul; 6(7):1962-72. PubMed ID: 17620427
[TBL] [Abstract][Full Text] [Related]
26. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
[TBL] [Abstract][Full Text] [Related]
27. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
29. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Blake S; Hughes TP; Mayrhofer G; Lyons AB
Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
[TBL] [Abstract][Full Text] [Related]
30. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Laschi M; Bernardini G; Geminiani M; Manetti F; Mori M; Spreafico A; Campanacci D; Capanna R; Schenone S; Botta M; Santucci A
Biofactors; 2017 Nov; 43(6):801-811. PubMed ID: 28786551
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
33. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Bartscht T; Lehnert H; Gieseler F; Ungefroren H
Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
[TBL] [Abstract][Full Text] [Related]
34. SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
Indovina P; Casini N; Forte IM; Garofano T; Cesari D; Iannuzzi CA; Del Porro L; Pentimalli F; Napoliello L; Boffo S; Schenone S; Botta M; Giordano A
J Cell Physiol; 2017 Jan; 232(1):129-35. PubMed ID: 27037775
[TBL] [Abstract][Full Text] [Related]
35. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
[TBL] [Abstract][Full Text] [Related]
36. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
Finn RS; Aleshin A; Dering J; Yang P; Ginther C; Desai A; Zhao D; von Euw E; Busuttil RW; Slamon DJ
Hepatology; 2013 May; 57(5):1838-46. PubMed ID: 23299860
[TBL] [Abstract][Full Text] [Related]
37. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
38. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
[TBL] [Abstract][Full Text] [Related]
39. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
van Oosterwijk JG; van Ruler MA; Briaire-de Bruijn IH; Herpers B; Gelderblom H; van de Water B; Bovée JV
Br J Cancer; 2013 Sep; 109(5):1214-22. PubMed ID: 23922104
[TBL] [Abstract][Full Text] [Related]
40. Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Pohorelic B; Singh R; Parkin S; Koro K; Yang AD; Egan C; Magliocco A
Breast Cancer Res Treat; 2012 May; 133(1):201-14. PubMed ID: 21894461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
